Abeona Therapeutics Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses), averaging -13.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.23 | $-0.35 | -52.2% | Miss | |
| Q1 FY26 | $-0.33 | $-0.30 | +9.1% | Beat | |
| Q4 FY25 | $-0.35 | $-0.34 | +2.9% | Beat |
Back to ABEO overview · ABEO holders · ABEO KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.